Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas

Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypes

Excerpt from the Press Release:

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating cirtuvivint in patients with advanced soft-tissue sarcomas. The multicenter, open-label trial, led by Principal Investigator Dr. Javier Martin Broto, is sponsored by SELNET (Sarcoma European and Latin American Network) and is being conducted at eight clinical sites across Spain.

This Investigator Initiated Trial follows a preclinical collaboration and focuses on specific sarcoma subtypes, aiming to assess the safety and efficacy of cirtuvivint as a monotherapy. SELNET elected to sponsor the trial following a comprehensive review of preclinical data, which demonstrated compelling activity of cirtuvivint across multiple soft-tissue sarcoma cell lines and xenograft models that were refractory to other treatments.

The “Multicenter, Open-Label Phase 2 Trial of Cirtuvivint as a Second-Line Therapy in Selected Advanced Soft-Tissue Sarcomas” will evaluate cirtuvivint monotherapy in approximately 30 patients whose disease has progressed following initial standard of care. The trial focuses on specific sarcoma subtypes and aims to assess the safety and efficacy of cirtuvivint in this difficult-to-treat patient population.

Click the button below to read the entire Press Release:

Continue Reading The Press Release